AR040226A1 - Productos parenterales antifungicos - Google Patents

Productos parenterales antifungicos

Info

Publication number
AR040226A1
AR040226A1 ARP030102119A ARP030102119A AR040226A1 AR 040226 A1 AR040226 A1 AR 040226A1 AR P030102119 A ARP030102119 A AR P030102119A AR P030102119 A ARP030102119 A AR P030102119A AR 040226 A1 AR040226 A1 AR 040226A1
Authority
AR
Argentina
Prior art keywords
antifungic
parenteral pharmaceutical
parenteral products
echinocandin
pharmaceutical formulations
Prior art date
Application number
ARP030102119A
Other languages
English (en)
Inventor
Martin Stogniew
Original Assignee
Vicuron Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicuron Pharm Inc filed Critical Vicuron Pharm Inc
Publication of AR040226A1 publication Critical patent/AR040226A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Abstract

Formulaciones farmacéuticas parenterales que contienen un compuesto antifúngico de equinocandina y un solvente acuoso, en donde la formulación incluye etanol, por ejemplo aproximadamente 20% p/v de etano (desde aproximadamente 5% p/v hasta aproximadamente 50% p/v de etanol). La formulación farmacéutica parenteral puede incluir además uno o más aditivos, tales como un agente estabilizante, buffer o agente de tonicidad. Las formulaciones farmacéuticas parenterales son útiles para extender la vida en estante y mejorar la solubilidad del compuesto antifúngico de equinocandina.
ARP030102119A 2002-06-13 2003-06-13 Productos parenterales antifungicos AR040226A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/172,678 US6991800B2 (en) 2002-06-13 2002-06-13 Antifungal parenteral products

Publications (1)

Publication Number Publication Date
AR040226A1 true AR040226A1 (es) 2005-03-16

Family

ID=29733139

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102119A AR040226A1 (es) 2002-06-13 2003-06-13 Productos parenterales antifungicos

Country Status (11)

Country Link
US (2) US6991800B2 (es)
EP (1) EP1511378A2 (es)
JP (1) JP4972750B2 (es)
KR (1) KR100800503B1 (es)
AR (1) AR040226A1 (es)
AU (1) AU2003248692B2 (es)
CA (1) CA2488872A1 (es)
IL (1) IL165720A0 (es)
NO (1) NO20051648L (es)
TW (1) TW200400831A (es)
WO (1) WO2003105767A2 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743777B1 (en) * 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
EP1156782B1 (en) * 1999-03-03 2005-05-04 Eli Lilly And Company Echinocandin pharmaceutical formulations containing micelle-forming surfactants
ES2204548T3 (es) 1999-03-03 2004-05-01 Eli Lilly And Company Complejos de equinocandina/carbohidrato.
US6991800B2 (en) * 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
US20090252807A1 (en) * 2005-04-13 2009-10-08 Elan Pharma International Limited Nanoparticulate and Controlled Release Compositions Comprising Prostaglandin Derivatives
WO2009048544A1 (en) * 2007-10-10 2009-04-16 Merck & Co., Inc. Liquid pharmaceutical compositions for parenteral administration of a substituted amide
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
JP2013503179A (ja) * 2009-08-27 2013-01-31 シーチェイド ファーマシューティカルズ，インコーポレーテッド エキノキャンディン誘導体
HUE036778T2 (hu) 2011-03-03 2018-07-30 Cidara Therapeutics Inc Gombaellenes szerek és alkalmazásuk
PL3238709T3 (pl) 2011-04-28 2021-02-08 Platform Brightworks Two, Ltd. Ulepszone preparaty pozajelitowe lipofilowych środków farmaceutycznych oraz sposoby ich wytwarzania i stosowania
DK2827710T3 (da) * 2012-03-19 2020-02-03 Cidara Therapeutics Inc Doseringsskema for echinocandin-klasse-forbindelser
RU2719579C2 (ru) * 2013-03-14 2020-04-21 Сидара Терапьютикс, Инк. Режимы дозирования для соединений класса эхинокандинов
EA201791100A1 (ru) * 2014-11-19 2017-11-30 Гуфик Байосайенсиз Лимитед Способ получения парентерального состава на основе анидулафунгина
CN105641678A (zh) * 2014-12-03 2016-06-08 博瑞生物医药（苏州）股份有限公司 阿尼芬净胃肠外制剂及制备方法
ES2694561T3 (es) * 2015-02-23 2018-12-21 Selectchemie Ag Composición de anidulafungina
WO2017047299A1 (ja) * 2015-09-15 2017-03-23 富士フイルム株式会社 注射用液剤組成物
CN108883152A (zh) 2016-01-08 2018-11-23 奇达拉治疗公司 防止和治疗肺孢子虫感染的方法
EP4268896A3 (en) 2016-03-16 2024-01-03 Cidara Therapeutics, Inc. Dosing regimens for treatment of fungal infections
CN106729723A (zh) * 2016-11-21 2017-05-31 青岛农业大学 一种含匹莫苯丹的药物组合物及其制备方法
US20180169180A1 (en) * 2016-12-16 2018-06-21 Baxter International Inc. Micafungin compositions
CA3069423A1 (en) 2017-07-12 2019-01-17 Cidara Therapeutics, Inc. Formulations for the treatment of fungal infections
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
CN109481665B (zh) * 2018-12-05 2019-08-06 广州迈达康医药科技有限公司 一种注射用阿尼芬净复溶药剂及其制备方法
CA3132923A1 (en) * 2019-03-08 2020-09-17 Emphascience, Inc. Stable pharmaceutical formulations of peptide and protein drugs
MX2022006085A (es) * 2019-11-22 2023-03-01 Leiutis Pharmaceuticals Llp Formulaciones parenterales estables de duloxetina.
KR102162727B1 (ko) 2020-04-22 2020-10-07 주식회사 이뮤니스바이오 인간 세포 유래 소포체와 세포의 동시 투여를 통한 새로운 세포치료제 조성물
CN114015758B (zh) * 2021-10-15 2022-06-24 无锡百泰克生物技术有限公司 一种冻干保护剂、荧光pcr检测试剂盒及冻干工艺

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US54981A (en) * 1866-05-22 Improvement in nail-machines
US161176A (en) * 1875-03-23 Improvement in heaters for cheese-vats
US160942A (en) * 1875-03-16 Improvement in farm-boxes
US151474A (en) * 1874-06-02 Improvement in corn-shellers
US2002A (en) * 1841-03-12 Tor and planter for plowing
US3293482A (en) * 1962-06-21 1966-12-20 Rca Corp Plural output traveling wave tube
JPS5134916B2 (es) * 1974-03-06 1976-09-29
DE2803581A1 (de) 1978-01-27 1979-08-02 Sandoz Ag Derivate des tetrahydro-echinocandin b
CA1170598A (en) 1979-12-13 1984-07-10 Bernard J. Abbott Process for the preparation of cyclic peptide nuclei
CA1183127A (en) 1979-12-13 1985-02-26 Manuel Debono Process for the preparation of derivatives of cyclic peptide nuclei
US4293482A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company A-30912A Nucleus
US4293489A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company Derivatives of A-30912A nucleus
US4293483A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company Derivatives of A-30912A nucleus
US4304716A (en) * 1979-12-13 1981-12-08 Eli Lilly And Company S 31794/F-1 Nucleus
US4320052A (en) * 1979-12-13 1982-03-16 Eli Lilly And Company Derivatives of A-30912A nucleus
US4299763A (en) * 1979-12-13 1981-11-10 Eli Lilly And Company A-30912B Nucleus
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
US4876241A (en) * 1987-05-22 1989-10-24 Armour Pharmaceutical Company Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
US5166135A (en) * 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
DK173802B1 (da) 1988-09-12 2001-11-05 Merck & Co Inc Præparat til behandling af Pneumocystis carinii infeksioner og anvendelse af et cyclohexapeptid til fremstilling af et lægemiddel mod Pneumocystis carinii infektioner
US4927831A (en) * 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
AU617541B2 (en) 1988-10-20 1991-11-28 Wyeth Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
US5202309A (en) * 1989-06-30 1993-04-13 Merck & Co., Inc. Antibiotic cyclopeptide fermentation product
JPH03240727A (ja) 1990-02-15 1991-10-28 Toyo Jozo Co Ltd ニューモシスチス・カリニ肺炎治療剤
CA2037957A1 (en) 1990-03-12 1991-09-13 Merck & Co., Inc. N-acylated cyclohexapeptide compounds
GB2241956A (en) 1990-03-16 1991-09-18 Merck & Co Inc N-acylated cyclohexapeptide compounds
US5310726A (en) 1990-03-19 1994-05-10 Merck & Co., Inc. Lipopeptide compounds
US5049546A (en) 1990-03-19 1991-09-17 Merck & Co., Inc. Antibiotic agents
US5330973A (en) 1990-03-19 1994-07-19 Merck & Co., Inc. Lipopeptide derivatives
IL97347A0 (en) 1990-03-19 1992-05-25 Merck & Co Inc Lipopeptide derivatives and antimicrobial compositions containing them
US5386009A (en) 1990-03-19 1995-01-31 Merck & Co. Inc. Lipopeptide derivatives
IE910892A1 (en) 1990-03-19 1991-09-25 Merck & Co Inc Lipopeptide compounds
DK0460882T3 (da) 1990-06-07 1996-08-26 Lilly Co Eli Lipopeptiddeacylase
IL98506A (en) 1990-06-18 1996-09-12 Fujisawa Pharmaceutical Co Peptides, of antibiotics, processes for their preparation and pharmaceutical preparations containing them
US5198421A (en) * 1991-04-26 1993-03-30 Merck & Co., Inc. Phosphorylated cyclic lipopeptide
EP0486011A3 (en) 1990-11-16 1992-07-15 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition against pneumocystis carinii
US5369093A (en) 1991-03-15 1994-11-29 Merck & Co., Inc. Lipopeptide derivatives
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5233023A (en) 1991-07-30 1993-08-03 Merck & Co., Inc. Process for phosphate ester compounds of certain cyclohexapeptides
JPH05271097A (ja) 1991-10-07 1993-10-19 Asahi Chem Ind Co Ltd アクレアシン類の可溶化剤および医薬組成物
US6743777B1 (en) * 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
NZ512085A (en) 1992-03-19 2003-08-29 Lilly Co Eli Methods employing cyclic peptide antifungal agents
US5965525A (en) * 1992-03-19 1999-10-12 Eli Lilly And Company Cyclic peptide antifungal agents
US6384013B1 (en) * 1992-03-19 2002-05-07 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
EP0589074B1 (en) 1992-09-22 2001-11-21 Takeo Dr. Takayanagi Carbohydrate complexes for destruction of resistant cancer cells
JPH06172205A (ja) 1992-12-11 1994-06-21 Asahi Chem Ind Co Ltd アクレアシン類含有脂肪乳剤
US5383324A (en) 1993-04-23 1995-01-24 Baxter International Inc. Method for manufacturing and storing stable bicarbonate solutions
EP0697879A4 (en) * 1993-05-04 1998-01-14 Merck & Co Inc AMINOALKYL ETHERS OF CYCLOHEXAPEPTIDYLE
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US5541160A (en) * 1994-04-04 1996-07-30 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5646111A (en) * 1995-04-07 1997-07-08 Eli Lilly And Company Cyclic peptide antifungal Agents
US5618787A (en) * 1995-05-26 1997-04-08 Eli Lilly And Company Cyclic peptide antifungal agents
US5652213A (en) * 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
US5786325A (en) * 1995-05-26 1998-07-28 Eli Lilly And Company Cyclic peptide antifungal agents and methods of making and using
US5629290A (en) * 1995-05-26 1997-05-13 Eli Lilly And Company Cyclic peptide antifungal agents
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5629289A (en) 1995-07-25 1997-05-13 Eli Lilly And Company Cyclic peptide antifungal agents
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
US5693611A (en) * 1996-02-01 1997-12-02 Eli Lilly And Company Cyclic peptide antifungal agents
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5696084A (en) * 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
AU5719798A (en) * 1996-12-31 1998-07-31 Inhale Therapeutic Systems, Inc. Processes for spray drying aqueous suspensions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
CA2301184A1 (en) * 1997-08-04 1999-02-11 Eli Lilly And Company Cyclic peptide antifungal agents
US5972996A (en) * 1997-08-22 1999-10-26 Merck & Co., Inc. 4-cyano-4-deformylsordarin derivatives
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
EP0931834A3 (en) 1997-12-23 2002-06-26 Eli Lilly And Company Echinocandin binding domain of 1,3-Beta-glucan synthase
DE19800287A1 (de) * 1998-01-07 1999-07-08 Bayer Ag Aliphatische sinterfähige thermoplastische Polyurethanformmassen mit reduzierter mechanischer Festigkeit
US6323176B1 (en) * 1998-02-25 2001-11-27 Eli Lilly And Company Cyclic peptide antifungal agents
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6451349B1 (en) * 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
JP2002528388A (ja) * 1998-08-20 2002-09-03 イーライ リリー アンド カンパニー 環改変された環状ペプチドアナログ
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DK1137663T3 (da) * 1998-12-09 2007-01-08 Lilly Co Eli Oprensning af Echinocandin-cyclopeptidforbindelser
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
JP4063497B2 (ja) * 1999-03-03 2008-03-19 イーライ リリー アンド カンパニー エキノカンジンアンモニウム塩結晶の形成およびアニオン交換
ES2204548T3 (es) 1999-03-03 2004-05-01 Eli Lilly And Company Complejos de equinocandina/carbohidrato.
IL145188A0 (en) 1999-03-03 2002-06-30 Lilly Co Eli Processes for making pharmaceutical oral ecb formulations and compositions
EP1156782B1 (en) * 1999-03-03 2005-05-04 Eli Lilly And Company Echinocandin pharmaceutical formulations containing micelle-forming surfactants
US6258821B1 (en) * 1999-04-26 2001-07-10 Medimmune Oncology, Inc. Compositions comprising trimetrexate and methods of their synthesis and use
US7914799B2 (en) * 2001-08-27 2011-03-29 Immunitor USA, Inc. Anti-fungal composition
US6991800B2 (en) * 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products

Also Published As

Publication number Publication date
TW200400831A (en) 2004-01-16
WO2003105767A2 (en) 2003-12-24
EP1511378A2 (en) 2005-03-09
IL165720A0 (en) 2006-01-15
AU2003248692A1 (en) 2003-12-31
KR20050016552A (ko) 2005-02-21
WO2003105767A3 (en) 2004-04-01
NO20051648L (no) 2005-04-04
US20050261173A1 (en) 2005-11-24
KR100800503B1 (ko) 2008-02-04
WO2003105767A8 (en) 2005-05-19
AU2003248692B2 (en) 2008-07-31
US6991800B2 (en) 2006-01-31
JP4972750B2 (ja) 2012-07-11
CA2488872A1 (en) 2003-12-24
US7198796B2 (en) 2007-04-03
JP2005533056A (ja) 2005-11-04
US20040223997A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
AR040226A1 (es) Productos parenterales antifungicos
ECSP055582A (es) Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor
ATE433447T1 (de) Pyrimiidinverbindungen
CL2004000849A1 (es) Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras.
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
AR051778A2 (es) Derivados del acido dimetilaminocrotonico y procesos para supreparacion
EP1472230A4 (en) ANSAMYCINS WITH IMPROVED PHARMACOLOGICAL AND BIOLOGICAL PROPERTIES
CY1105167T1 (el) Συνθεσεις πepιεχουσες ενα κοσμετολογικα ενepγο οργανικο οξυ και ενα προϊον οσπριου
ECSP055640A (es) Composiciones de pirazol útiles como inhibidores de gsk-3
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
ECSP055529A (es) Composicion herbicida
ATE386725T1 (de) Heterocyclylverbindungen
PA8532001A1 (es) Bifenilcarboxamidas utiles como agentes reductores de lipidos
AR063263A1 (es) Agentes tensioactivos reconstituidos
FI964285A (fi) Taksaanien luokkaan kuuluviin johdannaisiin perustuvat farmaseuttiset valmisteet
PL376176A1 (en) Solid preparation
EA201990501A1 (ru) Фармацевтическая композиция
PA8542601A1 (es) Bifenilcarboxamidas reductoras de lipidos
EP2292227A3 (en) Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity
MX2009005299A (es) Maiz extraido con solvente.
BRPI0417366A (pt) composição detergente lìquida, método de limpeza de um substrato de tecido, e, uso de um antioxidante
AR013462A1 (es) Nuevos peptidomimeticos para el tratamiento de trastornos oseos, metodos para su produccion y drogas que contienen estos compuestos
ECSP045372A (es) Inhibidores de la carboxipeptidasa b plasmática
ES2481450T3 (es) Proteasas específicas de ubiquitina responsables de la estabilidad de mcl 1 y su utilización
CL2004001579A1 (es) Composicion farmaceutica que comprende un analogo de somatostatina y acido tartarico, donde la composicion tiene el ph regulado entre 4 y 4,5 y el compuesto activo es l ciclo[{4-(nh2-c2h4-nh-cp-o)pro}-phg-dtrp-lys-tyr(4-bzl)-phe]; y su uso para prepa

Legal Events

Date Code Title Description
FB Suspension of granting procedure